摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-{2-[4-(2-amino-1H-imidazol-4-yl)phenyl]ethyl}thiazol-2-yl)acetamide hydrochloride | 1442469-24-0

中文名称
——
中文别名
——
英文名称
N-(4-{2-[4-(2-amino-1H-imidazol-4-yl)phenyl]ethyl}thiazol-2-yl)acetamide hydrochloride
英文别名
N-[4-[2-[4-(2-amino-1H-imidazol-5-yl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide;hydrochloride
N-(4-{2-[4-(2-amino-1H-imidazol-4-yl)phenyl]ethyl}thiazol-2-yl)acetamide hydrochloride化学式
CAS
1442469-24-0
化学式
C16H17N5OS*ClH
mdl
——
分子量
363.871
InChiKey
QKAPQTIDKJDIFE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.28
  • 重原子数:
    24
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    125
  • 氢给体数:
    4
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    tert-butyl (4-{4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl}-1H-imidazol-2-yl)carbamate盐酸 作用下, 以 甲醇乙酸乙酯 为溶剂, 反应 10.0h, 以76%的产率得到N-(4-{2-[4-(2-amino-1H-imidazol-4-yl)phenyl]ethyl}thiazol-2-yl)acetamide hydrochloride
    参考文献:
    名称:
    Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment
    摘要:
    Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50 = 0.019 mu M, rat IC50 = 0.0051 mu M). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2013.04.011
点击查看最新优质反应信息